Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Capital Reinvestment Ratio
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Capital Reinvestment Ratio of 1.44x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥11.57 Million) in capital expenditures (CN¥16.64 Million). See Hubei Biocause Heilen Pharmaceutical Co. free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Capital Reinvestment Ratio (2018–2025)
This chart tracks Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2018–2025)
Year-by-year Capital Reinvestment Ratio for Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2018 to 2025. For live market cap and broader valuation context, see Hubei Biocause Heilen Pharmaceutical Co. market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 6.93x | CN¥7.55 Million | CN¥52.33 Million | ▲ +304.9% |
| 2024 | 1.71x | CN¥96.07 Million | CN¥164.43 Million | ▲ +25.8% |
| 2023 | 1.36x | CN¥137.06 Million | CN¥186.53 Million | ▲ +349.4% |
| 2022 | 0.30x | CN¥250.79 Million | CN¥75.95 Million | ▲ +78.2% |
| 2021 | 0.17x | CN¥123.98 Million | CN¥21.07 Million | ▲ +54.4% |
| 2020 | 0.11x | CN¥121.67 Million | CN¥13.39 Million | ▲ +26.7% |
| 2019 | 0.09x | CN¥372.33 Million | CN¥32.34 Million | ▼ -73.6% |
| 2018 | 0.33x | CN¥76.18 Million | CN¥25.08 Million | — |